Alumis Inc. ALMS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -31.05%
- 1 year
- +44.42%
- Open
- 6.84
- Prev close
- 6.89
- Mkt cap
- 871.10M
- Vol
- 2.24M
- Avg vol
- 2.67M
- EPS
- -3.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.46
- High
- 6.92
- Forward P/E
- -2.82
- Beta
- -0.79
- Short ratio
- 6.42
- Inst. own
- 93.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 21.50
- 200-d avg
- 22.28
- 1y target
- 32.13
News
2 weeks ago defenseworld.net
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27
Alumis Inc. (NASDAQ: ALMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One…
-
3 weeks ago benzinga.com
Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis–…
3 weeks ago globenewswire.com
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib's potential to become a leading oral therapy for moderate-to-severe plaque psoriasis –…
3 weeks ago defenseworld.net
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis
Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
1 month ago defenseworld.net
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
1 month ago defenseworld.net
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)
Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies…
1 month ago seekingalpha.com
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
226,618 Shares in Alumis Inc. $ALMS Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second quarter, according to its most recent filing with the SEC. The firm acquired 226,618 shares of the…
1 month ago globenewswire.com
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with…
-
2 months ago benzinga.com
Oppenheimer Maintains Outperform on Alumis, Lowers Price Target to $37
Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $55 to $37.
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on Alumis, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $51 to $25.
2 months ago benzinga.com
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
2 months ago benzinga.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Alumis, Lowers Price Target to $29
Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the price target from $39 to $29.
-
2 months ago benzinga.com
HC Wainwright & Co. Upgrades Alumis to Buy, Lowers Price Target to $15
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to Buy and lowers the price target from $25 to $15.
2 months ago seekingalpha.com
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
2 months ago seekingalpha.com
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
2 months ago benzinga.com
Crude Oil Surges 3%; ISM Manufacturing PMI Falls In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.The Dow traded down 0.40% to 52,971.81 while the NASDAQ dipped 0.52% to 26,232.46.…
2 months ago marketbeat.com
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population.…
2 months ago benzinga.com
Why Is Alumis Stock Falling Tuesday?
Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-group data shows promise.
2 months ago benzinga.com
Dow Dips Over 300 Points; Medtronic Shares Gain After Upbeat Q1 Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ…
2 months ago reuters.com
Alumis eyes late-stage lupus study despite trial miss
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a…
-
2 months ago benzinga.com
Alumis Announces Its Phase 2b LUMUS Study Of Envudeucitinib To Treat Lupus Erythematosus Failed To Meet Primary, Secondary Endpoints
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS…
2 months ago globenewswire.com
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
-
2 months ago benzinga.com
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per…
2 months ago globenewswire.com
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
2 months ago defenseworld.net
California State Teachers Retirement System Raises Stock Position in Alumis Inc. $ALMS
California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 2,222.5% in the first quarter, according to its most recent disclosure with the Securities…
2 months ago zacks.com
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
2 months ago benzinga.com
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin…
2 months ago benzinga.com
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
-
2 months ago benzinga.com
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif.,…
-
3 months ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.
3 months ago defenseworld.net
Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next?
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline…
4 months ago seekingalpha.com
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety,…
5 months ago fool.com
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
-
5 months ago benzinga.com
Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40
Chardan Capital analyst Janani Sundararajan maintains Alumis (NASDAQ:ALMS) with a Buy and raises the price target from $38 to $40.
5 months ago benzinga.com
This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & UNTY with Buy ratings. See other analyst views.
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51
Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and raises the price target from $49 to $51.
-
5 months ago benzinga.com
Guggenheim Maintains Buy on Alumis, Raises Price Target to $34
Guggenheim analyst Yatin Suneja maintains Alumis (NASDAQ:ALMS) with a Buy and raises the price target from $32 to $34.
5 months ago benzinga.com
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
-
5 months ago benzinga.com
HC Wainwright & Co. Downgrades Alumis to Neutral, Maintains Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Alumis (NASDAQ:ALMS) from Buy to Neutral and maintains the price target from $25 to $25.
-
5 months ago benzinga.com
Alumis Q1 EPS $(0.74) Beats $(0.77) Estimate, Sales $1.741M Miss $2.767M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.77) by 3.9 percent. This is a 59.34 percent increase over losses of $(1.82) per…
7 months ago benzinga.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings
7 months ago benzinga.com
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst ratings page. Analysts' thoughts on LGND stock.
8 months ago benzinga.com
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
8 months ago benzinga.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
9 months ago benzinga.com
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
Peakstone Realty Trust, Aquestive Therapeutics, Opera And Other Big Stocks Moving Higher On Monday
9 months ago benzinga.com
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday